{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:13:43Z","timestamp":1786115623910,"version":"build-2736575974"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are the main subtypes of cutaneous T-cell lymphomas that are characterized by clinical heterogeneity and are difficult to cure. Objective: This retrospective study evaluated the efficacy and immunomodulatory effects of low-dose decitabine combined with camrelizumab, a novel PD-1 monoclonal antibody used to treat patients with refractory advanced MF\/SS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The enrolled patients received decitabine (10 mg\/d, days 1\u20135) combined with camrelizumab (200 mg, day 7) every 4 weeks. The response was assessed and peripheral blood was analyzed for T-cell subsets, cytokines, Lactate Dehydrogenase (LDH), \u03b22-microglobulin levels, and lymphocyte parameters. Adverse events were monitored.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>Results<\/jats:title>\n                      <jats:p>\n                        From February 2021 to May 2025, 14 patients were enrolled in the study (3 SS, 1 folliculotropic MF, and 6 with large-cell transformation). The objective response rate was 71.4% (10\/14), with 5 complete (CR) and 5 partial responses (PR). At a median of 13.5 months follow-up, 3 patients maintained sustained CR. Common adverse events were grade 1\u20132 leukopenia (21.4%), elevated transaminases (28.6%), and camrelizumab-related mucocutaneous capillary proliferation (50.0%). Exploratory immunophenotyping showed a progressive decline in the CD4\n                        <jats:sup>+<\/jats:sup>\n                        \/CD8\n                        <jats:sup>+<\/jats:sup>\n                        ratio, lower baseline LDH, and absolute lymphocyte counts in responders, whereas non-responders had significantly higher IL-5 and IL-13 levels (\n                        <jats:italic>P<\/jats:italic>\n                        &amp;lt;\u00a00.05).\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination regimen showed encouraging preliminary activity and tolerability in this small retrospective cohort, although the efficacy of SS remains suboptimal. These findings are hypothesis-generating and require prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1851475","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:53Z","timestamp":1785990293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose decitabine combined with camrelizumab for refractory\/relapsed mycosis fungoides\/S\u00e9zary syndrome: a retrospective exploratory study"],"prefix":"10.3389","volume":"16","author":[{"given":"Shan","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Hematology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liufang","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20757","article-title":"Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides","volume":"186","author":"Falkenhain-Lopez","year":"2022","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15224","article-title":"Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas","volume":"47","author":"Falkenhain-Lopez","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000517830","article-title":"Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment: real-life data from the German Cutaneous Lymphoma Network","volume":"238","author":"Blazejak","year":"2022","journal-title":"Dermatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2245-x","article-title":"Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)","volume":"106","author":"Atilla","year":"2017","journal-title":"Int J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102780","article-title":"The microenvironment's role in mycosis fungoides and Sezary syndrome: from progression to therapeutic implications","volume":"10","author":"Pileri","year":"2021","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody Camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16288","article-title":"Pathogenesis of cutaneous T cell lymphoma: involvement of Staphylococcus aureus","volume":"49","author":"Fujii","year":"2022","journal-title":"J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/life14020245","article-title":"Role of IL-4 and IL-13 in cutaneous T cell lymphoma","volume":"14","author":"Mazzetto","year":"2024","journal-title":"Life (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014655","article-title":"Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed\/refractory cutaneous T-cell lymphoma","volume":"9","author":"Querfeld","year":"2025","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5417","article-title":"Results from the EMBOLDEN trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma","author":"Roberts","year":""},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.022","article-title":"Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications","volume":"72","author":"Hsi","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from Malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1851475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:54Z","timestamp":1785990294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1851475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1851475"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1851475","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1851475"}}